Yakira Capital Management, Inc. Cerevel Therapeutics Holdings, Inc. Transaction History

Yakira Capital Management, Inc.

  • $197 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$38.96 - $42.75 $1.77 Million - $1.94 Million
45,496 Added 160.58%
73,829 $3.02 Million
Q1 2024

May 14, 2024
BUY
$40.88 - $43.27 $545,053 - $576,918
13,333 Added 88.89%
28,333 $1.2 Million
Q4 2023

Feb 13, 2024
BUY
$20.27 - $42.44 $304,050 - $636,600
15,000 New
15,000 $636,000

Others Institutions Holding CERE

# of Institutions
9
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Yakira Capital Management, Inc. Portfolio

Follow Yakira Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Yakira Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Yakira Capital Management, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email